Interestingly, correlative analysis of paired pre- and on-therapy fresh core biopsy and blood samples collected on the latter cohort of recurrent ovarian cancer found that treatment enhanced IFN-γ and CXCL9/CXCL10 expression, systemic IFN-γ/TNF-α production and TILs, creating a more immunostimulatory milieu [152]. Here, IFNG is linked to ovarian cancer.